S&P 500   3,634.41 (+1.59%)
DOW   30,085.94 (+1.67%)
QQQ   293.05 (+0.92%)
AAPL   114.56 (+0.62%)
MSFT   212.80 (+1.28%)
FB   273.90 (+2.04%)
GOOGL   1,751.20 (+1.37%)
AMZN   3,113.41 (+0.48%)
TSLA   544.88 (+4.41%)
NVDA   518.01 (-1.44%)
BABA   277.16 (+2.61%)
CGC   26.68 (+7.93%)
GE   10.59 (+5.16%)
MU   63.27 (-1.42%)
AMD   84.64 (-0.79%)
T   29.29 (+2.34%)
NIO   52.94 (-4.41%)
F   9.41 (+6.21%)
ACB   8.94 (+24.51%)
NFLX   480.82 (+0.88%)
GILD   60.72 (+1.39%)
BA   221.07 (+4.51%)
DIS   150.92 (+3.38%)
S&P 500   3,634.41 (+1.59%)
DOW   30,085.94 (+1.67%)
QQQ   293.05 (+0.92%)
AAPL   114.56 (+0.62%)
MSFT   212.80 (+1.28%)
FB   273.90 (+2.04%)
GOOGL   1,751.20 (+1.37%)
AMZN   3,113.41 (+0.48%)
TSLA   544.88 (+4.41%)
NVDA   518.01 (-1.44%)
BABA   277.16 (+2.61%)
CGC   26.68 (+7.93%)
GE   10.59 (+5.16%)
MU   63.27 (-1.42%)
AMD   84.64 (-0.79%)
T   29.29 (+2.34%)
NIO   52.94 (-4.41%)
F   9.41 (+6.21%)
ACB   8.94 (+24.51%)
NFLX   480.82 (+0.88%)
GILD   60.72 (+1.39%)
BA   221.07 (+4.51%)
DIS   150.92 (+3.38%)
S&P 500   3,634.41 (+1.59%)
DOW   30,085.94 (+1.67%)
QQQ   293.05 (+0.92%)
AAPL   114.56 (+0.62%)
MSFT   212.80 (+1.28%)
FB   273.90 (+2.04%)
GOOGL   1,751.20 (+1.37%)
AMZN   3,113.41 (+0.48%)
TSLA   544.88 (+4.41%)
NVDA   518.01 (-1.44%)
BABA   277.16 (+2.61%)
CGC   26.68 (+7.93%)
GE   10.59 (+5.16%)
MU   63.27 (-1.42%)
AMD   84.64 (-0.79%)
T   29.29 (+2.34%)
NIO   52.94 (-4.41%)
F   9.41 (+6.21%)
ACB   8.94 (+24.51%)
NFLX   480.82 (+0.88%)
GILD   60.72 (+1.39%)
BA   221.07 (+4.51%)
DIS   150.92 (+3.38%)
S&P 500   3,634.41 (+1.59%)
DOW   30,085.94 (+1.67%)
QQQ   293.05 (+0.92%)
AAPL   114.56 (+0.62%)
MSFT   212.80 (+1.28%)
FB   273.90 (+2.04%)
GOOGL   1,751.20 (+1.37%)
AMZN   3,113.41 (+0.48%)
TSLA   544.88 (+4.41%)
NVDA   518.01 (-1.44%)
BABA   277.16 (+2.61%)
CGC   26.68 (+7.93%)
GE   10.59 (+5.16%)
MU   63.27 (-1.42%)
AMD   84.64 (-0.79%)
T   29.29 (+2.34%)
NIO   52.94 (-4.41%)
F   9.41 (+6.21%)
ACB   8.94 (+24.51%)
NFLX   480.82 (+0.88%)
GILD   60.72 (+1.39%)
BA   221.07 (+4.51%)
DIS   150.92 (+3.38%)
Log in
NASDAQ:BIIB

Biogen Stock Forecast, Price & News

Trending Stocks   Most-Downgraded Stocks  
$242.28
-1.10 (-0.45 %)
(As of 11/24/2020 12:18 PM ET)
Add
Compare
Today's Range
$240.15
Now: $242.28▼
$243.50
50-Day Range
$236.26
MA: $269.62▼
$355.63
52-Week Range
$223.25
Now: $242.28▼
$374.99
Volume31,010 shs
Average Volume1.75 million shs
Market Capitalization$37.28 billion
P/E Ratio8.02
Dividend YieldN/A
Beta0.61
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More
Biogen logo

Beat the Market (BTM) Rank™

Analyst Opinion: 4.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

2.01 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
Previous Symbol
CUSIP09062X10
CIK875045
Webwww.biogen.com
Phone617-679-2000
Employees7,400

Debt

Debt-to-Equity Ratio0.69
Current Ratio2.06
Quick Ratio1.79

Price-To-Earnings

Trailing P/E Ratio8.02
Forward P/E Ratio7.21
P/E Growth1.12

Sales & Book Value

Annual Sales$14.38 billion
Price / Sales2.59
Cash Flow$38.34 per share
Price / Cash Flow6.32
Book Value$69.82 per share
Price / Book3.47

Profitability

EPS (Most Recent Fiscal Year)$33.57
Net Income$5.89 billion
Net Margins35.63%
Return on Equity51.00%
Return on Assets23.54%

Miscellaneous

Outstanding Shares153,882,000
Market Cap$37.28 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$242.28
-1.10 (-0.45 %)
(As of 11/24/2020 12:18 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biogen (NASDAQ:BIIB) Frequently Asked Questions

How has Biogen's stock price been impacted by Coronavirus?

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIIB shares have decreased by 18.2% and is now trading at $240.81.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Biogen?

33 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 sell ratings, 15 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Biogen.

What stocks does MarketBeat like better than Biogen?

Wall Street analysts have given Biogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Biogen.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its earnings results on Wednesday, October, 21st. The biotechnology company reported $8.84 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $8.06 by $0.78. The biotechnology company earned $3.38 billion during the quarter, compared to analysts' expectations of $3.34 billion. Biogen had a return on equity of 51.00% and a net margin of 35.63%. Biogen's quarterly revenue was down 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $9.17 earnings per share.
View Biogen's earnings history.

How will Biogen's stock buyback program work?

Biogen declared that its Board of Directors has authorized a stock buyback program on Monday, December 23rd 2019, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, October, 21st. The company provided earnings per share (EPS) guidance of 32.50-33.50 for the period, compared to the Thomson Reuters consensus estimate of $34.77. The company issued revenue guidance of $13.2-13.4 billion, compared to the consensus revenue estimate of $13.83 billion.

What price target have analysts set for BIIB?

33 brokers have issued 12-month target prices for Biogen's stock. Their forecasts range from $175.00 to $450.00. On average, they expect Biogen's stock price to reach $305.90 in the next year. This suggests a possible upside of 27.0% from the stock's current price.
View analysts' price targets for Biogen.

Are investors shorting Biogen?

Biogen saw a increase in short interest in October. As of October 30th, there was short interest totaling 3,800,000 shares, an increase of 26.2% from the October 15th total of 3,010,000 shares. Based on an average daily volume of 1,530,000 shares, the short-interest ratio is presently 2.5 days. Approximately 2.5% of the shares of the stock are sold short.
View Biogen's Short Interest.

Who are some of Biogen's key competitors?

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR).
View all competitors.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

Who are Biogen's key executives?

Biogen's management team includes the following people:
  • Mr. Michel Vounatsos, CEO & Director (Age 58, Pay $5.72M)
  • Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 63, Pay $1.99M)
  • Dr. Alfred W. Sandrock Jr., Exec. VP of R&D (Age 62, Pay $1.87M)
  • Mr. Chirfi Guindo, Exec. VP of Global Product Strategy & Commercialization (Age 54, Pay $1.32M)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 56)
  • Ms. Robin C. Kramer, VP & Chief Accounting Officer (Age 54)
  • Mr. Mark J. Hernon, Sr. VP & Chief Information Officer (Age 56)
  • Mr. Joe Mara, VP of Fin. & Head of Investor Relations
  • Ms. Natacha Gassenbach, Chief Communication Officer & Head of Corp. Affairs
  • Dr. Ginger Gregory, Exec. VP & Chief HR Officer (Age 52)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.40%), State Street Corp (4.89%), AQR Capital Management LLC (1.44%), UBS Asset Management Americas Inc. (0.86%), LSV Asset Management (0.62%) and Wells Fargo & Company MN (0.49%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen.

Which major investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, AJO LP, State Street Corp, Allianz Asset Management GmbH, Nuveen Asset Management LLC, Assenagon Asset Management S.A., Voloridge Investment Management LLC, and BlackRock Inc.. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, Brian S Posner, and Stephen A Sherwin.
View insider buying and selling activity for Biogen.

Which major investors are buying Biogen stock?

BIIB stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, DekaBank Deutsche Girozentrale, Robeco Institutional Asset Management B.V., Acadian Asset Management LLC, Point72 Asset Management L.P., DNB Asset Management AS, BNP PARIBAS ASSET MANAGEMENT Holding S.A., and O Shaughnessy Asset Management LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $240.81.

How big of a company is Biogen?

Biogen has a market capitalization of $37.06 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.